{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-21-000052","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.123005+00:00","generated_at":"2026-06-28T10:07:43.349421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Werewolf Therapeutics Q3 net loss $13.8M; cash $170.4M; Merck collaboration for WTX-124","bullets":["Net loss of $13.8M versus $6.1M in Q3 2020; R&D expenses $9.8M, G&A $4.0M.","Cash and equivalents $170.4M, up from $92.6M at year-end 2020; runway through Q2 2023.","Entered clinical trial collaboration with Merck to evaluate WTX-124 + KEYTRUDA in solid tumors.","On track to file INDs for WTX-124 and WTX-330 in first half of 2022.","Appointed Meeta Chatterjee, Ph.D., to board of directors in October 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-21-000052","json":"https://secwatch.observer/filing/0001785530-21-000052.json","markdown":"https://secwatch.observer/filing/0001785530-21-000052.md","text":"https://secwatch.observer/filing/0001785530-21-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/0001785530-21-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/howl-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:07:43.349421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}